# Furosemide as Supportive Therapy for COVID-19 Respiratory Failure

> **NCT04588792** · PHASE2,PHASE3 · TERMINATED · sponsor: **Dr. John Muscedere** · enrollment: 40 (actual)

## Conditions studied

- Covid19
- Respiratory Failure

## Interventions

- **DRUG:** Nebulized Furosemide
- **DRUG:** Nebulized Saline

## Key facts

- **NCT ID:** NCT04588792
- **Lead sponsor:** Dr. John Muscedere
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-16
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-04-30
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Lack of recruitment due to decline in critically ill Covid-19 patients
- **Last updated:** 2023-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04588792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04588792, "Furosemide as Supportive Therapy for COVID-19 Respiratory Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04588792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*